Showing 3 results for Rheumatoid
Beri Tawfeq, Bizav Rasheed,
Volume 0, Issue 0 (7-2024)
Abstract
Background and objectives: Rheumatoid arthritis (RA) is a long-term autoimmune disorder that primarily affects joints. The disease may also affect other parts of the body, including the skin, eyes, lungs, heart, nerves, and blood. Aim and objectives: To evaluate the effect of methotrexate on blood, liver, and renal parameters in Rheumatoid arthritis.
Methods: A six-month cross-sectional study was carried out on 60 consecutive patients of aged 19–70 years with diagnosed Rheumatoid arthritis on methotrexate treatment (10 mg) orally per week. A questionnaire form was taken from participants, and laboratory tests were done on renal and liver function and serological tests (complete blood count, erythrocyte sedimentation rate, glutamic pyruvic transaminase, a glutamic-oxaloacetic transaminase, creatinine, C-reactive protein, and rheumatoid factor as follow-up of drug taking).
Results: At the end of sample collection, age 19–70 years, female: male ratio 1.5:1, while the only significant differences in platelet level were between day one and fourteen of treatment with a P value < 0.05, Glutamic Pyruvic Transaminase (GPT) level was between day one and thirty with a P value < 0.05, and rheumatoid factor level was between day one, fourteen, and day one, thirty with P values of (0.01) and (0.04) respectively which were significant.
Conclusion: The recommended medication for all kinds of rheumatoid arthritis patients is methotrexate, which has had a notable impact on blood, liver, and kidney parameters. These characteristics could be used to track how well this medication works, how safe it is, and to follow up with patients.
Abdollahi, E. (bsc), Tavasolian, F. (bsc), Vakili, M. (phd), Samadi, M. (phd),
Volume 9, Issue 1 (4-2015)
Abstract
Abstract
Background and Objective: C- reactive protein (CRP), as an acute phase reactant and a reliable marker of inflammation, increases due to inflammatory diseases such as Rheumatoid Arteritis and infectious conditions. New evidence shows that Vitamin D may have important effects on adjusting and reducing the Immune Responses. The aim of this study was to evaluate the association between serum vitamin D as an immunomodulator factor and CRP as an inflammatory factor in Arteritis Patients. .
Material and Methods: The CRP and Vitamin D were evaluated in Rheumatoid Arteritis patients confirmed by Medical records (40 men and 40 women) and in 80 healthy adult people with normal CRP and Vitamin D and no history of arteritis (40 men and 40 women). Torbidometry was used to measure CRP and Eliza for Vitamin D.
Results: In patient group, the mean of CRP and Vitamin D were 95.9±9.1 Mlg/lit and 9.17±2.9 Mlg/lit, resoectively. There was a significant inverse correlation between C-reactive protein and vitamin D in Rheumatoid Arteritis patients (Pvalue= 0.03 Pearson correlation: -0.62) and that was the case for healthy people (p value: 0.04 Pearson correlation: -0.73).
Conclusion: Based on the findings, inverse correlation is observed between serum vitamin D and CRP level.
Keywords: Vitamin D, CRP, Rheumatoid Arteritis
Hadi Bazzazi, Yaghoub Yazdani, Nasser Behnampour, Hadi Hossein-Nataj, Ali Memarian, Mehrdad Aghaei,
Volume 13, Issue 6 (11-2019)
Abstract
ABSTRACT
Background and Objectives: T helper (Th) lymphocytes play a key role in the pathogenesis of autoimmune diseases. As a new subset of lymphocytes, Th9 is thought to be involved in a wide range of disorders including rheumatoid arthritis (RA). In this study, we evaluated frequency of Th9 and Th2 cells and its correlation with disease activity in patients with different stages of RA.
Methods: The frequency of circulating interleukin 9- and/or interleukin 4-producing CD3+CD8-T cells was determined among 41 patients with established RA, 14 patients with very early RA (VERA) and 23 healthy controls by flow cytometry analysis. Then, correlation of cell frequencies with disease activity score 28 (DAS-28) was assessed. Serum levels of interleukin 6 and anti-citrullinated peptide antibodies were measured by enzyme-linked immunosorbent assay.
Results: Frequency of Th9 cells was significantly higher in RA patients compared to healthy controls (P=0.009). Moreover, mean percentage of circulating Th9 cells in patients with inactive VERA was significantly higher than that in those with active disease (P=0.046). In addition, mean percentage of Th9 cells had a negative correlation with the DAS-28 (r=-0.568, P<0.05). There was no significant correlation between the mean serum level of interleukin 6 and percentage of Th2 and Th9 cells (P>0.05).
Conclusion: Our results suggest that Th9 cells may have a potential role in RA initiation. Thus, targeting Th9 cells could be a promising strategy for advanced RA therapies.
Keywords: Rheumatoid arthritis, Th2 cells, Th9 cells.
